

Supporting Information

Efficient Synthesis of Bioactive Isoindolinone Derivatives Containing Continuous Quaternary Carbons by Intermolecular OH Transfer

Yingying He,^a Hongtao Li,^b Longlong Song,^a Lili Chen,^b Shunying Liu^{*a}

a. Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.

b. Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

*Corresponding authors. syliu@sist.ecnu.edu.cn

Table of Contents

| | |
|--|----|
| 1. General information..... | 2 |
| 2. Optimization of reaction conditions | 4 |
| 3. Examples of unreactive substrates..... | 6 |
| 4. General procedure..... | 7 |
| 5. Single crystal X-ray diffraction data of <i>anti</i> - 3e (CDCC NO.: 2308679) | 8 |
| 6. References..... | 10 |
| 7. Characterization data for the products 3 | 11 |
| 8. ¹ H, ¹⁹ F and ¹³ C NMR spectra for products 3 | 19 |

1. General information

All ^1H NMR (400 MHz) and ^{13}C NMR (100 MHz) and ^{19}F NMR (376 MHz) spectra were recorded on Bruker spectrometers in CDCl_3 . Tetramethylsilane (TMS) served as an internal standard ($\delta = 0$) for ^1H NMR, and CD_3OD , CD_3CN or CDCl_3 was used as internal standard ($\delta = 49.0$, $\delta = 1.3$, 118.3 or $\delta = 77.0$) for ^{13}C NMR. Chemical shifts are reported in parts per million as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad). High-resolution mass spectrometry (HRMS) was performed on IonSpec FT-ICR mass spectrometer. Single crystal X-ray diffraction data were recorded on Bruker-AXS SMART APEX II single crystal X-ray diffractometer. Yields for all compounds were combined yields for all isomers unless otherwise indicated.

3-Hydroxyisoindolin-1-ones **3**¹ and diazo compounds² were prepared according to the literature methods. The benzyl alcohols were purchased from Sahn Chemical Technology Ltd and used without further purification. All reactions and manipulations were carried out under air atmosphere in a flame-dried or oven-dried flask containing magnetic stir bar. Dichloromethane (DCM), 1,2-dichloroethane (DCE), THF and toluene was distilled over calcium hydride. Solvents for the column chromatography were distilled before use.

Expression and purification of SARS-CoV-2 3CL^{pro} was performed according to our previous methods.³ The plasmids were transformed into BE21 (DE3) cells, *E. coli* was incubated and grown overnight as starter cultures. Then it was used to expand the culture at a 1:50 dilution, and then the cultures were further grown at 220 rpm, 37 °C until the OD600 reached 0.6-0.7. Protease expression was induced by addition of 0.3 mM IPTG, the cultures were incubated at 18 °C, 180 rpm for 16 h. Collected cells were sonicated in buffer (25 mM Tris, 150 mM NaCl, 20 mM imidazole, 1 mM DTT, pH 7.4) and the lysate was centrifuged at 4 °C for 30 min at 12000 rpm. 2 mL of Ni NTA agarose (GE Healthcare) was added to the supernatant for binding overnight. The miscellaneous proteins were eluted with a low concentration of imidazole, and the SARS-CoV-2 3CL^{pro} was eluted with 300 mM

imidazole. SARS-CoV-2 3CL^{pro} was dialyzed through a dialysis membrane with a truncated molecular weight of 10 kDa and stored in solution (25 mM HEPES, 150 mM NaCl, 1 mM DTT, pH 7.4) for experiments.

The *in vitro* SARS-CoV-2 3CL^{pro} bioactivity was detected by our previous method.³ The fluorogenic peptide Dabcyl-KNSTLQSGLRK-Edans was synthesized (Genscript, Nanjing, China), then resuspended in DMSO at 10 mM and used as a substrate. For the measurement of inhibition ratio, SARS-CoV-2 3CL^{pro} in the assay buffer (1×PBS, 1 mM EDTA, pH 7.4) was added to 96 well plate at a final concentration of 0.12 μM. Test compounds were prepared in assay buffer and then added to the wells for 30 min at 37 °C. Substrates were added at 20 μM to initiate the reaction for 20 min at 37 °C. The fluorescence (Excitation 340 nm, Emission 490 nm) was measured using a Cytation 5 plate reader (BioTek, USA). Data were processed through GraphPad Prism 8.0.

2. Optimization of reaction conditions

Scheme S1. Exploring the effect of varying the equivalent of H₂O on yield





Table S1. Optimization of reaction conditions^a




| entry | temp. (°C) | catalyst | acid | solvent | x (mol%) | yield ^b (%) | dr ^c |
|-------|------------|---|-----------------------------------|------------------|----------|------------------------|-----------------|
| 1 | 25 | Rh ₂ (OAc) ₄ | TsOH | DCM ^d | 60 | 78 | 1:2 |
| 2 | 25 | Rh ₂ (OAc) ₄ | TsOH | DCM | 60 | 80 | 1:2 |
| 3 | 25 | [PdCl(η ³ -C ₃ H ₅)] ₂ | TsOH | DCM | 60 | 71 | 1:2 |
| 4 | 25 | Rh ₂ (s-nttl) ₄ | TsOH | DCM | 60 | 73 | 1:2 |
| 5 | 25 | Cu(OTf) ₂ | TsOH | DCM | 60 | <5 | 1:2 |
| 6 | 25 | Rh ₂ (OAc) ₄ | H ₃ PO ₄ | DCM | 60 | 70 | 1:2 |
| 7 | 25 | Rh ₂ (OAc) ₄ | CH ₃ SO ₃ H | DCM | 60 | 73 | 1:2 |
| 8 | 25 | Rh ₂ (OAc) ₄ | CF ₃ COOH | DCM | 60 | 53 | 1:2 |
| 9 | 25 | Rh ₂ (OAc) ₄ | CH ₃ COOH | DCM | 60 | 64 | 1:2 |
| 10 | -20 | Rh ₂ (OAc) ₄ | TsOH | DCM | 60 | 84 | 1:2 |
| 11 | 0 | Rh ₂ (OAc) ₄ | TsOH | DCM | 60 | 88 | 1:2 |
| 12 | 40 | Rh ₂ (OAc) ₄ | TsOH | DCM | 60 | 73 | 1:2 |
| 13 | 0 | Rh ₂ (OAc) ₄ | TsOH | DCE | 60 | 77 | 1:2 |
| 14 | 0 | Rh ₂ (OAc) ₄ | TsOH | Toluene | 60 | 74 | 1:2 |
| 15 | 0 | Rh ₂ (OAc) ₄ | TsOH | THF | 60 | 80 | 1:2 |
| 16 | 25 | Rh ₂ (OAc) ₄ | TsOH | DCM | 10 | 69 | 1:2 |
| 17 | 25 | Rh ₂ (OAc) ₄ | TsOH | DCM | 60 | 83 | 1:2 |
| 18 | 25 | Rh ₂ (OAc) ₄ | TsOH | DCM | 90 | 84 | 1:2 |
| 19 | 25 | Rh ₂ (OAc) ₄ | TsOH | DCM | 120 | 82 | 1:2 |

^a Unless otherwise noted, all reactions were conducted on a 0.1 mmol scale of **1a**, **1a:2a** = 1:1.5 and solvents were of analytical reagent grade. Due to the lower reaction yield when **1a:2a** was in a 1:1 ratio after 4 hours, the equivalent of **2a** was increased to 1.5, allowing **1a** to be fully reacted within 4 hours. ^b Combined yield of *anti*- and *syn*-isomers after isolation. ^c The ratio of diastereomers (dr) was determined by ¹H NMR of the crude products. ^d The reaction of entry 1 proceeded with ultradry solvent.

3. Examples of unreactive substrates


Scheme S2. Examples of unreactive substrates^a



^a Unless otherwise noted, all reactions were conducted in the 2mL mixture solvent of **1** (0.3 mmol) and the catalyst, and **2** (0.45 mmol) was added dropwise by syringe pump at a flow rate of 1 mL/h at 0 °C.


4. General procedure

4.1 General procedure for the synthesis of 3-Aryl-3-hydroxyisoindolin-1-ones¹



A solution of aryl bromide (3.0 equiv) in THF (50 mL) was taken in an oven-dried RB flask and cooled to $-78\text{ }^{\circ}\text{C}$. To the solution was added drop wise *n*-butyllithium (3 equiv, 12 mL, 2.5 M in hexane, 30 mmol), and the mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 0.5 h. To the solution was added phthalimide (1 equiv, 10 mmol) and the mixture was stirred for further 15 min at $-78\text{ }^{\circ}\text{C}$ and for 4h at room temperature. Upon completion (monitored by TLC), the reaction mixture was quenched with saturated NH₄Cl solution. Then, aqueous solution was extracted with ethyl acetate (3 times). The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄, and concentrated in vacuo. The pure product was obtained by washing the crude product with CH₂Cl₂/hexane (1:3, v/v) as a solvent.

4.2 General procedure for the preparation of phenyl diazoester²



Under nitrogen, at room temperature, a round bottomed flask is charged with the phenylacetic acid (20 mmol, 1 equiv.), dry DCM (0.4 M), oxalyl chloride (1.5 equiv.). Then, DMF (1 or 2 drops) is added. The reaction is allowed to stir at room temperature for 2h. Then, the reaction temperature is cooled to 0 °C and an excess of alcohol (x mL) is added. The reaction is allowed to warm up to room temperature and to stir at this temperature overnight. Then, the reaction is quenched with a saturated aqueous solution of NaHCO₃, extracted with AcOEt (3x mL), dried with MgSO₄ and concentrated under reduced pressure. The solvent was removed and the crude product was obtained used directly in the next step. To a mixture of the crude product obtained above (20 mmol) and tosyl azide (*p*-ABSA) (30 mmol) in anhydrous CH₃CN (20 mL), 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) (30 mmol) was added slowly. The reaction mixture was stirred at room temperature for overnight. Upon complete consumption of the starting materials, the reaction mixture was quenched with saturated aqueous solution of NH₄Cl (5 mL), extracted with CH₂Cl₂ (3 × 30 mL), washed by brine. The combined extracts were dried with Na₂SO₄ and concentrated. The residue was purified by flash chromatography (PE/EA, 50:1) to afford the phenyl diazoester.


The method for the crystal growth of *anti-3e* is as follows: *anti-3e* (15 mg) was stored in a 2.0 mL mixture of DCM/EA (v/v, 4:1) solvents in a refrigerator at 4 °C for five days, and 1.5 mL of an equal proportion of the mixed solution was continually added to the bottle. The bottle continued to be stored in under same conditions for three days.

6. References

- [1] (a) T. Nishimura, A. Noishiki, Y. Ebe and T. Hayashi, Hydroxorhodium/Chiral Diene Complexes as Effective Catalysts for the Asymmetric Arylation of 3-Aryl-3-hydroxyisoindolin-1-ones, *Angew. Chem. Int. Ed.*, 2013, **52**, 1777–1780; (b) J. Suć, I. Dokli and M. Gredičak, Chiral Brønsted acid-catalysed enantioselective synthesis of isoindolinone-derived N (acyl), S-acetals, *Chem. Commun.*, 2016, **52**, 2071–2074; (c) Y. P. Ruan, M. D. Chen, M. Z. He, X. Zhou and P. Q. Huang, A Practical Two-Step Synthesis of 3-Alkyl-2, 3-dihydro-1*H*-isoindolin-1-ones, *Synth. Commun.*, 2004, **34**, 853–861; (d) J. Q. Zhou, W. J. Sheng, J. H. Jia, Q. Ye, J. R. Gao and Y. X. Jia, Chiral phosphoric acid catalyzed asymmetric hydrogenolysis of racemic 3-aryl-3-hydroxyisoindolin-1-ones, *Tetrahedron Lett.*, 2013, **54**, 3082–3084; (e) A. Suneja, R. A. Unhale and V. K. Singh, Enantioselective hydrophosphonylation of in situ generated N-acyl ketimines catalyzed by BINOL-derived phosphoric acid, *Org. Lett.*, 2017, **19**, 476–479; (f) R. A. Unhale, N. Molleti, N. K. Rana, S. Dhanasekaran, S. Bhandary and V. K. Singh, Chiral phosphoric acid catalyzed enantioselective addition of thiols to in situ generated ketimines: Synthesis of N, S-ketals, *Tetrahedron Lett.*, 2017, **58**, 145–151.
- [2] S. Thurow, A. A. G. Fernandes, Y. Quevedo-Acosta, M. F. de Oliveira, M. G. de Oliveira, I. D. Jurberg, Preparation of Organic Nitrates from Aryldiazoacetates and $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$, *Org. Lett.*, 2019, **21**, 6909–6913.
- [3] R. Wang, Q. Hu, H. Wang, G. Zhu, M. Wang, Q. Zhang, Y. Zhao, C. Li, Y. Zhang, G. Ge, H. Chen and L. Chen, Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL^{pro}, *Int. J. Biol. Macromol.*, 2021, **183**, 182–192.

7. Characterization data for the products 3

Methyl 2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)-2-phenylacetate (3a). White solid, *syn/anti* isomer (2:5) ratio.




3a

(*syn* : *anti* = 2:5)

Mixture of (*syn* : *anti* = 2:5) isomers of **3a** (88% yield): $^1\text{H NMR}$ (400 MHz, Methanol- d_4) δ 8.35 (d, $J = 7.9$ Hz, 1H), 8.06 (d, $J = 7.9$ Hz, 2.5H), 7.84 (d, $J = 9.0$ Hz, 4.5H), 7.62 (t, $J = 7.6$ Hz, 1H), 7.57 – 7.52 (m, 3.5H), 7.47 – 7.42 (m, 3H), 7.40 – 7.32 (m, 7.5H), 7.20 (d, $J = 7.7$ Hz, 5H), 7.17 – 7.07 (m, 5.5H), 7.01 (t, $J = 7.6$ Hz, 5H), 6.85 (d, $J = 9.0$ Hz, 5H), 6.76 (d, $J = 8.9$ Hz, 2H), 3.75 (s, 7.5H), 3.74 (s, 3H), 3.70 (s, 7.5H), 3.55 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Methanol- d_4) δ 174.6, 173.6, 172.3, 172.1, 171.5, 160.54, 160.48, 149.7, 148.8, 139.1, 133.9, 133.1, 132.6, 132.54, 132.48, 131.4, 130.9, 129.6, 129.5, 129.3, 129.2, 129.1, 128.5, 128.29, 128.26, 128.2, 128.1, 128.0, 123.8, 123.4, 114.4, 113.7, 85.3, 84.2, 73.8, 72.1, 55.63, 55.60, 53.1, 53.0. **HRMS(ESI)** Calcd. for $\text{C}_{24}\text{H}_{21}\text{NNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 426.1312, found 426.1305.

Methyl 2-(4-chlorophenyl)-2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)acetate (3b). White solid, *syn/anti* isomer (1:1) ratio.




3b

(*syn* : *anti* = 1:1)

Mixture of (*syn* : *anti* = 1:1) isomers of **3b** (83% yield): $^1\text{H NMR}$ (400 MHz, Acetonitrile- d_3) δ 8.23 (d, $J = 7.9$ Hz, 1H), 8.07 (d, $J = 7.8$ Hz, 1H), 7.91 (s, 1H), 7.79 (d, $J = 8.9$ Hz, 2H), 7.64 (d, $J = 7.8$ Hz, 2H), 7.56 (dd, $J = 15.4, 7.1$ Hz, 2H), 7.47 (t, $J = 7.4$ Hz, 1H), 7.42 – 7.33 (m, 6H), 7.23 (d, $J = 8.6$ Hz, 2H), 7.16 (d, $J = 8.6$ Hz, 2H), 7.07 (d, $J = 8.6$ Hz, 2H), 6.88 (d, $J = 8.8$ Hz, 2H), 6.80 (d, $J = 8.9$ Hz, 2H), 5.01 (s, 1H), 4.87 (s, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 3.73 (s, 3H), 3.56 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Acetonitrile- d_3) δ 173.6, 172.8, 169.8, 169.6, 160.1, 160.0, 148.0, 147.5, 137.3, 137.2, 134.7, 134.6, 133.5, 132.5, 132.4, 130.8, 130.4, 130.0, 129.8, 129.6, 129.4, 129.3, 128.2, 127.9, 127.64, 127.62, 123.7, 123.2, 114.3, 113.7, 84.3, 83.3, 72.3, 70.6, 55.8, 53.9, 53.8. **HRMS(ESI)** Calcd. for $\text{C}_{24}\text{H}_{20}\text{ClNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 460.0922, found 460.0949.

Methyl 2-(4-bromophenyl)-2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)acetate (3c). White solid, *syn/anti* isomer (2:3) ratio.




3c

(*syn* : *anti* = 2:3)

Mixture of (*syn* : *anti* = 2:3) isomers of **3c** (89% yield): $^1\text{H NMR}$ (400 MHz, Chloroform- d) δ 8.14 (d, $J = 7.8$ Hz, 1.5H), 8.06 (d, $J = 7.8$ Hz, 1H), 7.82 (s, 1H), 7.76 (t, $J = 8.4$ Hz, 3.5H), 7.63 (t, $J = 7.5$ Hz, 1.5H), 7.55 – 7.47 (m, 3.5H), 7.37 – 7.32 (m, 7H), 7.23 (s, 3H), 7.18 (s, 4H), 7.03 (s, 1.5H), 6.85 (d, $J = 8.7$ Hz, 2H), 6.76 (d, $J = 8.7$ Hz, 3H), 4.34 (s, 1.5H), 4.10 (s, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.77 (s, 4.5H), 3.57 (s, 4.5H). $^{13}\text{C NMR}$ (100 MHz, Chloroform- d) δ 172.7, 172.3, 169.8, 169.4, 159.3, 159.2, 146.7, 146.3, 135.7, 135.5, 132.3, 131.9, 131.7, 131.3, 131.0, 130.7, 130.5, 129.2, 129.1, 129.0, 128.8, 128.7,


128.5, 128.3, 126.3, 126.0, 123.8, 123.3, 123.0, 113.7, 113.1, 83.4, 82.0, 70.6, 69.7, 55.2, 53.8. **HRMS(ESI)** Calcd. for $C_{24}H_{20}BrNNaO_5$ ($M + Na$)⁺ 504.0417, found 504.0411.

Methyl 2-(3-bromophenyl)-2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)acetate (3d). White solid, *syn/anti* isomer (1:1) ratio.



anti-3d


anti-3d (38% yield): **¹H NMR** (400 MHz, Acetonitrile-*d*₃) δ 8.07 (d, $J = 7.8$ Hz, 1H), 7.92 (s, 1H), 7.78 (d, $J = 8.9$ Hz, 2H), 7.58 (t, $J = 7.0$ Hz, 1H), 7.39 – 7.26 (m, 5H), 7.01 (t, $J = 7.9$ Hz, 1H), 6.88 (d, $J = 8.8$ Hz, 2H), 5.07 (s, 1H), 3.76 (s, 3H), 3.73 (s, 3H). **¹³C NMR** (100 MHz, Acetonitrile-*d*₃) δ 173.4, 169.7, 168.7, 160.1, 147.9, 140.9, 132.43, 132.38, 132.0, 131.0, 129.8, 129.5, 129.3, 127.7, 126.8, 123.2, 121.7, 114.4, 84.3, 70.6, 55.8, 54.0. **HRMS(ESI)** Calcd. for $C_{24}H_{20}BrNNaO_5$ ($M + Na$)⁺ 504.0417, found 504.0423.



syn-3d


syn-3d (38% yield): **¹H NMR** (400 MHz, Acetonitrile-*d*₃) δ 8.24 (d, $J = 7.9$ Hz, 1H), 7.64 (dd, $J = 16.4, 8.7$ Hz, 2H), 7.53 (d, $J = 7.3$ Hz, 1H), 7.49 (d, $J = 7.7$ Hz, 2H), 7.40 (d, $J = 8.9$ Hz, 3H), 7.35 (d, $J = 8.2$ Hz, 1H), 7.09 (t, $J = 8.0$ Hz, 1H), 6.81 (d, $J = 8.9$ Hz, 2H), 3.75 (s, 3H), 3.57 (s, 3H). **¹³C NMR** (100 MHz, Acetonitrile-*d*₃) δ 172.2, 169.2, 159.7, 147.0, 140.4, 138.4, 133.1, 132.1, 131.7, 130.9, 130.4, 130.0, 129.8, 129.5, 127.3, 126.7, 123.3, 121.7, 82.9, 72.1, 55.5, 53.5. **HRMS(ESI)** Calcd. for $C_{24}H_{20}BrNNaO_5$ ($M + Na$)⁺ 504.0417, found 504.0438.

Methyl 2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)-2-(3-(trifluoromethyl)phenyl)acetate (3e). White solid, *syn/anti* isomer (1:3) ratio.



anti-3e

anti-3e (38% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.09 (d, $J = 7.8$ Hz, 1H), 7.85 – 7.75 (m, 3H), 7.62 – 7.52 (m, 2H), 7.44 (d, $J = 7.6$ Hz, 2H), 7.39 – 7.32 (m, 2H), 7.22 (t, $J = 7.9$ Hz, 1H), 6.86 (d, $J = 8.4$ Hz, 2H), 4.16 (s, 1H), 3.82 (s, 3H), 3.79 (s, 3H). **¹³C NMR** (100 MHz, Chloroform-*d*) δ 172.6, 169.8, 159.5, 146.5, 137.5, 131.9, 131.3, 130.5, 130.04, 129.96, 129.7, 128.9, 128.4, 127.8, 126.4, 125.36 (q, $J = 3.9$ Hz), 124.17 (q, $J = 3.6$ Hz), 123.3, 113.9, 83.5, 69.9, 55.4, 54.0. **¹⁹F NMR** (376 MHz, Chloroform-*d*) δ -62.84. **HRMS(ESI)** Calcd. for $C_{25}H_{20}F_3NNaO_5$ ($M + Na$)⁺ 494.1186, found 494.1198.



3e


(*syn* : *anti* = 1:1)

Mixture of (*syn* : *anti* = 1:1) isomers of 3e (38% yield): **¹H NMR** (400 MHz, Chloroform-*d*) δ 8.40 (s, 1H), 8.14 (dd, $J = 7.5, 3.7$ Hz, 2H), 7.83 – 7.77 (m, 3H), 7.73 (d, $J = 6.8$ Hz, 1H), 7.64 (t, $J = 7.2$ Hz, 2H), 7.57 (d, $J = 7.7$ Hz, 2H), 7.51 – 7.44 (m, 4H), 7.39 – 7.27 (m, 6H), 7.17 (t, $J = 7.9$ Hz, 1H), 6.86 (d, $J = 8.8$ Hz, 2H), 6.76 (d, $J = 8.8$ Hz, 2H), 4.46 (s, 1H), 4.34 (s, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.76 (s, 3H), 3.64 (s, 3H). **¹³C NMR** (100 MHz, Chloroform-*d*) δ 172.7, 172.2, 170.1, 159.43, 159.40, 146.5, 146.1, 137.64, 137.60, 132.5, 131.9, 131.8, 131.5, 130.5, 130.24, 130.17, 130.1, 129.92, 129.85, 129.6, 129.3, 129.2, 128.80, 128.75, 128.5, 128.3, 127.7, 126.5, 126.2, 125.45 (q, $J = 3.6$ Hz), 125.30, 125.21 (q, $J = 3.7$ Hz), 125.81 (q, $J = 3.6$ Hz), 124.22 (q, $J = 3.7$ Hz), 123.9, 123.2, 122.6, 122.5, 113.8, 113.3, 83.4, 82.4, 71.5, 70.2,

55.4, 55.3, 54.0, 53.9. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -62.70, -62.82. HRMS(ESI) Calcd. for $\text{C}_{25}\text{H}_{20}\text{F}_3\text{NNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 494.1186, found 494.1204.

Methyl 2-(3-chloro-4-fluorophenyl)-2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)acetate (3f).

White solid, *syn/anti* isomer (1:1) ratio.




anti-**3f**

anti-**3f** (38.5% yield): ^1H NMR (400 MHz, Acetonitrile-*d*₃) δ 8.07 (d, J = 7.8 Hz, 1H), 7.88 (s, 1H), 7.77 (d, J = 8.9 Hz, 2H), 7.62 – 7.56 (m, 1H), 7.38 (d, J = 3.7 Hz, 2H), 7.32 (dd, J = 7.2, 2.2 Hz, 1H), 7.28 – 7.23 (m, 1H), 6.94 (t, J = 8.9 Hz, 1H), 6.88 (d, J = 8.9 Hz, 2H), 5.08 (s, 1H), 3.76 (s, 3H), 3.73 (s, 3H). ^{13}C NMR (100 MHz, Acetonitrile-*d*₃) δ 173.2, 169.7, 160.2, 159.6 (d, J = 1.2 Hz), 157.1, 147.7, 135.9 (d, J = 3.7 Hz), 132.5 (d, J = 8.0 Hz), 132.1, 130.5, 129.6, 129.3, 128.5 (d, J = 7.6 Hz), 127.6, 123.3, 119.9 (d, J = 17.7 Hz),

116.0 (d, J = 21.0 Hz), 114.4, 83.9, 70.7, 55.8, 54.1. ^{19}F NMR (376 MHz, Acetonitrile-*d*₃) δ -118.10.

HRMS(ESI) Calcd. for $\text{C}_{24}\text{H}_{19}\text{ClFNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 478.0828, found 478.0849.




syn-**3f**

syn-**3f** (38.5% yield): ^1H NMR (400 MHz, Chloroform-*d*) δ 8.25 (s, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 8.6 Hz, 2H), 7.59 – 7.51 (m, 2H), 7.36 (dd, J = 16.2, 7.8 Hz, 2H), 7.28 (s, 1H), 6.83 (dd, J = 20.5, 8.7 Hz, 3H), 4.22 (s, 1H), 3.83 (s, 3H), 3.78 (s, 3H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 172.6, 159.3 (d, J = 23.6 Hz), 156.7, 146.5 (d, J = 2.5 Hz), 133.6 (d, J = 3.5 Hz), 131.9, 130.5 (d, J = 2.5 Hz), 129.8, 128.9, 128.5, 127.0, 126.9 (d, J = 7.6 Hz), 126.5, 123.4, 120.3 (d, J = 18.5 Hz), 115.5, 115.3, 113.9, 83.0, 70.1, 55.4, 54.1. ^{19}F NMR (376 MHz, Chloroform-*d*) δ -115.41. HRMS(ESI) Calcd. For $\text{C}_{24}\text{H}_{19}\text{ClFNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 478.0828, found 478.0849.

Methyl 2-(4-chloro-3-fluorophenyl)-2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)acetate (3g).

White solid, *syn/anti* isomer (1:1) ratio.




3g

(*syn* : *anti* = 1:1)

Mixture of (*syn* : *anti* = 1:1) isomers of **3g** (78% yield): ^1H NMR (400 MHz, Methanol-*d*₄) δ 8.36 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.58 (t, J = 9.5 Hz, 2H), 7.50 – 7.43 (m, 4H), 7.39 (d, J = 7.2 Hz, 1H), 7.28 (d, J = 11.3 Hz, 1H), 7.20 (s, 2H), 7.14 – 7.06 (m, 3H), 6.85 (d, J = 8.7 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 3.75 (s, 3H), 3.74 (s, 3H), 3.71 (s, 3H), 3.55 (s, 3H). ^{13}C NMR (100 MHz, Methanol-*d*₄) δ 173.7, 172.8, 172.3, 172.0, 160.6z8, 160.65, 159.5, 159.3, 157.1, 156.9, 149.0, 148.2, 140.8, 140.74, 140.70, 140.6, 133.7, 132.83, 132.75, 132.43, 132.41,


130.8, 130.7, 130.3, 130.1, 130.0, 129.7, 129.5, 128.4, 128.2, 125.4, 125.3, 125.02, 125.0, 124.0, 123.6, 121.7, 121.6, 121.5, 121.4, 117.3, 117.0, 116.9, 116.9, 116.6, 114.8, 114.7, 114.5, 113.9, 84.5, 83.5, 73.8, 72.0, 55.6, 53.5, 53.3. ^{19}F NMR (376 MHz, Methanol-*d*₄) δ -117.78 (dd, J = 10.4, 7.2 Hz), -118.16 (d, J = 11.2 Hz), -118.43 (dd, J = 11.1, 7.3 Hz). HRMS(ESI) Calcd. for $\text{C}_{24}\text{H}_{19}\text{ClFNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 478.0828, found 478.0832.

Methyl 2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)-2-(m-tolyl)acetate (3h). White solid, *syn/anti* isomer (10:31) ratio.




Mixture of (*syn* : *anti* = 10:31) isomers of **3h** (84% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.17 (d, $J = 7.8$ Hz, 1H), 8.04 (d, $J = 7.8$ Hz, 3.1H), 7.79 (d, $J = 8.9$ Hz, 6.2H), 7.75 (d, $J = 7.5$ Hz, 1H), 7.61 (d, $J = 6.9$ Hz, 4.1H), 7.52 (t, $J = 7.5$ Hz, 4.1H), 7.48 – 7.43 (m, 4.1H), 7.32 (t, $J = 7.4$ Hz, 4H), 7.23 – 7.17 (m, 3.1H), 7.11 (d, $J = 7.1$ Hz, 2H), 7.03 – 7.00 (m, 3.1H), 6.95 – 6.94 (m, 9.3H), 6.84 (d, $J = 8.9$ Hz, 6.2H), 6.73 (d, $J = 8.9$ Hz, 2H), 4.29 (s, 1H), 4.00 (s, 3.1H), 3.79 – 3.74 (m, 21.6H), 3.54 (s, 3H), 2.24 (s, 3H), 2.10 (s, 9.3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 173.1, 172.9, 169.9, 169.5, 159.23, 159.16, 147.3, 146.8, 137.7, 137.1, 136.7, 136.6, 132.5, 131.8, 131.6, 131.53, 131.49, 129.6, 129.5, 129.4, 129.3, 129.1, 128.5, 128.3, 128.2, 128.0, 127.9, 127.5, 127.4, 126.4, 126.1, 124.3, 123.74, 123.70, 123.1, 113.8, 112.9, 84.1, 82.3, 70.5, 69.9, 55.3, 53.7, 53.6, 21.7, 21.5. **HRMS(ESI)** Calcd. for $\text{C}_{25}\text{H}_{23}\text{NNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 440.1468, found 440.1475.

Methyl 2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)-2-(naphthalen-2-yl)acetate (3i). White solid, *syn/anti* isomer (1:5) ratio.




anti-3i (73% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.13 (d, $J = 7.8$ Hz, 1H), 7.84 – 7.80 (m, 2H), 7.71 – 7.66 (m, 3H), 7.61 (d, $J = 7.6$ Hz, 1H), 7.57 – 7.51 (m, 2H), 7.43 – 7.32 (m, 4H), 7.29 (d, $J = 7.4$ Hz, 1H), 6.88 – 6.84 (m, 2H), 4.09 (s, 1H), 3.81 (s, 3H), 3.79 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 173.1, 169.8, 159.3, 150.6, 147.2, 134.1, 133.0, 132.3, 131.7, 131.42, 131.39, 128.62, 128.59, 128.4, 127.5, 127.1, 126.7, 126.4, 126.2, 124.0, 123.3, 113.8, 84.2, 70.0, 55.4, 53.7. **HRMS(ESI)** Calcd. for $\text{C}_{28}\text{H}_{23}\text{NNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 476.1468, found 476.1462.

Benzyl 2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)-2-phenylacetate (3j). White solid, *syn/anti* isomer (1:1) ratio.




anti-3j (41% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.98 (d, $J = 7.8$ Hz, 1H), 7.74 (dd, $J = 9.6, 2.6$ Hz, 2H), 7.53 – 7.48 (m, 1H), 7.43 (d, $J = 7.5$ Hz, 1H), 7.37 – 7.28 (m, 4H), 7.20 – 7.15 (m, 3H), 7.15 – 7.09 (m, 3H), 7.04 (t, $J = 7.6$ Hz, 2H), 6.77 (dd, $J = 9.6, 2.6$ Hz, 2H), 5.23 (d, $J = 11.8$ Hz, 1H), 5.11 (d, $J = 11.8$ Hz, 1H), 3.96 (s, 1H), 3.79 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 172.5, 169.7, 159.3, 147.2, 136.7, 134.0, 131.7, 131.4, 131.3, 129.2, 129.1, 128.9, 128.8, 128.6, 128.3, 127.5, 126.7, 126.4, 123.1, 113.8, 84.0, 69.7, 69.0, 55.3. **HRMS(ESI)** Calcd. for $\text{C}_{30}\text{H}_{25}\text{NNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 502.1625, found 502.1607.

Benzyl 2-hydroxy-2-(1-(4-methoxyphenyl)-3-oxoisindolin-1-yl)-2-phenylacetate (3j). White solid, *syn/anti* isomer (1:1) ratio.




syn-**3j** (41% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.11 (d, $J = 7.8$ Hz, 1H), 7.58 (d, $J = 7.5$ Hz, 1H), 7.55 – 7.50 (m, 1H), 7.46 – 7.42 (m, 2H), 7.38 (d, $J = 7.4$ Hz, 1H), 7.36 – 7.31 (m, 3H), 7.27 (s, 1H), 7.20 (d, $J = 7.8$ Hz, 2H), 7.18 – 7.15 (m, 2H), 7.13 (d, $J = 8.9$ Hz, 2H), 6.68 (d, $J = 9.0$ Hz, 3H), 5.04 (d, $J = 11.7$ Hz, 1H), 4.89 (d, $J = 11.7$ Hz, 1H), 4.29 (s, 1H), 3.75 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 172.2, 169.3, 159.2, 146.5, 136.9, 133.9, 132.4, 131.7, 129.43, 129.39, 129.3, 129.04, 129.01, 128.91, 128.85, 128.0, 127.2, 126.1, 123.8, 113.0, 82.2, 70.5, 69.2, 55.3. **HRMS(ESI)** Calcd. for $\text{C}_{30}\text{H}_{25}\text{NNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 502.1625, found 502.1617.

Methyl 2-(6-chloropyridin-3-yl)-2-hydroxy-2-(1-(4-methoxy-3-methylphenyl)-3-oxoisindolin-1-yl)acetate (3k). White solid, *syn/anti* isomer (1:1) ratio.




Mixture of (*syn* : *anti* = 1:1) isomers of **3k** (73% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 9.00 (s, 1H), 8.44 – 8.37 (m, 2H), 8.28 – 8.17 (m, 2H), 8.04 (d, $J = 7.8$ Hz, 1H), 7.81 – 7.73 (m, 3H), 7.64 (dd, $J = 12.8, 6.4$ Hz, 3H), 7.60 – 7.48 (m, 3H), 7.38 (t, $J = 7.5$ Hz, 1H), 7.23 (d, $J = 8.3$ Hz, 2H), 7.09 (d, $J = 8.5$ Hz, 1H), 6.97 (d, $J = 8.5$ Hz, 1H), 6.78 (d, $J = 8.6$ Hz, 1H), 6.71 (d, $J = 8.2$ Hz, 1H), 4.54 (s, 1H), 4.45 (s, 1H), 3.88 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.66 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 172.5, 171.9, 157.8, 152.2, 151.7, 151.5, 149.1, 148.7, 146.3, 145.9, 139.9, 138.3, 137.6, 132.5, 132.1, 132.0, 131.6, 131.5, 131.3, 130.3, 129.6, 129.4, 129.3, 129.1, 127.94, 127.89, 126.62, 126.59, 126.5, 126.3, 126.1, 125.8, 124.9, 123.9, 123.5, 123.0, 122.7, 109.7, 109.3, 82.1, 81.5, 72.0, 70.4, 55.4, 54.3, 54.0, 16.7, 16.6. **HRMS(ESI)** Calcd. for $\text{C}_{24}\text{H}_{21}\text{ClN}_2\text{NaO}_5$ ($\text{M} + \text{Na}$) $^+$ 475.1031, found 475.1059.

3-(1-hydroxy-2-oxo-2-phenylethyl)-3-(4-methoxyphenyl)isindolin-1-one (3l). White solid, *syn/anti* isomer (1:1) ratio.




anti-**3l** (43.5% yield): $^1\text{H NMR}$ (400 MHz, Acetonitrile-*d*₃) δ 7.94 (d, $J = 7.7$ Hz, 2H), 7.71 (dd, $J = 15.3, 7.6$ Hz, 2H), 7.65 – 7.59 (m, 2H), 7.51 – 7.44 (m, 6H), 6.79 (d, $J = 8.8$ Hz, 2H), 6.13 (s, 1H), 3.69 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Acetonitrile-*d*₃) δ 200.1, 170.7, 160.0, 150.3, 136.9, 136.8, 134.8, 133.1, 133.0, 129.8, 129.6, 129.4, 127.5, 124.11, 124.06, 115.0, 74.1, 69.8, 55.8. **HRMS(ESI)** Calcd. for $\text{C}_{23}\text{H}_{19}\text{NNaO}_4$ ($\text{M} + \text{Na}$) $^+$ 396.1206, found 396.1223.

3-(1-hydroxy-2-oxo-2-phenylethyl)-3-(4-methoxyphenyl)isoindolin-1-one (3l). White solid, *syn/anti* isomer (1:1) ratio.




syn-**3l** (43.5% yield): $^1\text{H NMR}$ (400 MHz, Acetonitrile- d_3) δ 7.59 (d, $J = 8.7$ Hz, 3H), 7.53 (d, $J = 7.8$ Hz, 2H), 7.43 (d, $J = 7.6$ Hz, 1H), 7.41 – 7.36 (m, 2H), 7.24 – 7.18 (m, 3H), 7.17 – 7.12 (m, 1H), 6.92 (d, $J = 8.7$ Hz, 2H), 6.15 (s, 1H), 3.76 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Acetonitrile- d_3) δ 201.5, 170.1, 160.1, 148.3, 137.7, 133.7, 133.3, 132.7, 131.5, 129.4, 129.1, 129.0, 128.1, 125.7, 123.8, 114.8, 77.2, 70.4, 55.9. **HRMS(ESI)** Calcd. for $\text{C}_{23}\text{H}_{19}\text{NNaO}_4$ ($\text{M} + \text{Na}$) $^+$ 396.1206, found 396.1227.

Methyl 2-(4-bromophenyl)-2-hydroxy-2-(1-(4-methoxy-3-methylphenyl)-3-oxoisoindolin-1-yl)acetate (3n). White solid, *syn/anti* isomer (1:1) ratio.




anti-**3n** (39% yield): $^1\text{H NMR}$ (400 MHz, Chloroform- d) δ 8.29 (s, 1H), 8.11 (d, $J = 7.8$ Hz, 1H), 7.66 (d, $J = 8.6$ Hz, 1H), 7.60 – 7.49 (m, 3H), 7.34 (t, $J = 7.4$ Hz, 1H), 7.23 (d, $J = 8.5$ Hz, 2H), 7.16 (d, $J = 8.5$ Hz, 2H), 6.76 (d, $J = 8.7$ Hz, 1H), 4.19 (s, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 2.17 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform- d) δ 173.0, 170.2, 157.6, 146.9, 135.7, 131.7, 130.55, 130.51, 130.1, 129.6, 128.69, 128.65, 126.52, 126.48, 125.7, 123.3, 123.0, 109.6, 83.3, 70.0, 55.4, 53.9, 16.7. **HRMS(ESI)** Calcd. for $\text{C}_{25}\text{H}_{22}\text{BrNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 518.0574, found 518.0587.




syn-**3n** (39% yield): white solid. $^1\text{H NMR}$ (400 MHz, Chloroform- d) δ 8.13 (d, $J = 7.8$ Hz, 1H), 7.73 (d, $J = 7.5$ Hz, 1H), 7.63 (t, $J = 7.5$ Hz, 1H), 7.49 (t, $J = 7.5$ Hz, 1H), 7.35 (s, 4H), 7.10 – 7.02 (m, 2H), 6.80 (s, 1H), 6.67 (d, $J = 8.6$ Hz, 1H), 4.29 (s, 1H), 3.78 (s, 3H), 3.58 (s, 3H), 2.12 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform- d) δ 172.5, 169.4, 157.6, 146.4, 135.8, 132.3, 131.9, 131.0, 130.3, 129.22, 129.17, 128.4, 126.5, 126.2, 126.0, 123.9, 123.4, 109.1, 82.2, 70.7, 55.4, 53.9, 16.6. **HRMS(ESI)** Calcd. for $\text{C}_{25}\text{H}_{22}\text{BrNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 518.0574, found 518.0584.

Methyl 2-(4-bromophenyl)-2-hydroxy-2-(3-oxo-1-(4-phenoxyphenyl)isoindolin-1-yl)acetate (3o). White solid, *syn/anti* isomer (1:1) ratio.




anti-**3o** (33.5% yield): $^1\text{H NMR}$ (400 MHz, Chloroform- d) δ 8.27 (d, $J = 21.9$ Hz, 1H), 8.10 (d, $J = 7.8$ Hz, 1H), 7.82 (d, $J = 8.7$ Hz, 2H), 7.58 – 7.49 (m, 2H), 7.40 – 7.31 (m, 3H), 7.23 – 7.16 (m, 4H), 7.12 (t, $J = 7.4$ Hz, 1H), 6.97 (dd, $J = 19.3, 8.4$ Hz, 4H), 4.18 (d, $J = 5.8$ Hz, 1H), 3.83 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform- d) δ 172.8, 170.1, 157.5, 156.6, 146.6, 135.5, 133.3, 131.8, 131.5, 130.6, 130.0, 128.9, 128.8, 128.6, 126.5, 123.9, 123.4, 123.2, 119.6, 118.1, 83.4, 70.0, 54.0. **HRMS(ESI)** Calcd. for $\text{C}_{29}\text{H}_{22}\text{BrNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 566.0574, found 566.0535.

Methyl 2-(4-bromophenyl)-2-hydroxy-2-(3-oxo-1-(4-phenoxyphenyl)isoindolin-1-yl)acetate (3o). White solid, *syn/anti* isomer (1:1) ratio.




syn-3o (33.5% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.15 (d, $J = 7.7$ Hz, 1H), 7.76 (d, $J = 7.5$ Hz, 1H), 7.63 (t, $J = 7.6$ Hz, 1H), 7.51 (t, $J = 7.5$ Hz, 1H), 7.39 – 7.27 (m, 8H), 7.11 (t, $J = 7.4$ Hz, 1H), 6.97 (d, $J = 7.8$ Hz, 2H), 6.93 (s, 1H), 6.85 (d, $J = 8.8$ Hz, 2H), 4.36 (s, 1H), 3.57 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 172.4, 169.4, 157.4, 156.6, 146.2, 135.7, 132.4, 132.1, 131.4, 131.2, 130.0, 129.6, 129.4, 129.1, 126.1, 124.0, 123.9, 123.5, 119.5, 117.6, 82.1, 70.6, 54.0. **HRMS(ESI)** Calcd. for $\text{C}_{29}\text{H}_{22}\text{BrNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 566.0574, found 566.0545.

Methyl 2-(benzyloxy)-2-(4-bromophenyl)-2-(1-(4-(dimethylamino)phenyl)-3-oxoisoindolin-1-yl)acetate (3p). White solid, *syn/anti* isomer (2:3) ratio.




Mixture of (*syn* : *anti* = 2:3) isomers of **3p** (76% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.12 (s, 1H), 8.09 (d, $J = 7.7$ Hz, 1.5H), 7.87 (s, 1H), 7.77 (s, 1.5H), 7.66 (d, $J = 9.0$ Hz, 2H), 7.61 (t, $J = 7.6$ Hz, 1.5H), 7.54 – 7.45 (m, 4H), 7.39 – 7.29 (m, 8H), 7.22 (d, $J = 8.8$ Hz, 2H), 7.17 (dd, $J = 9.0, 2.9$ Hz, 5H), 6.65 (d, $J = 9.0$ Hz, 2H), 6.56 (d, $J = 9.0$ Hz, 3H), 4.32 (s, 1.5H), 4.11 (s, 1H), 3.79 (s, 3H), 3.58 (s, 4.5H), 2.93 (s, 6H), 2.91 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 172.9, 172.6, 150.1, 150.0, 147.1, 146.6, 136.0, 135.7, 132.5, 131.8, 131.6, 131.4, 130.9, 130.5, 129.3, 129.0, 128.8, 128.63, 128.55, 128.0, 126.4, 126.1, 125.6, 123.9, 123.4, 123.2, 123.0, 112.0, 111.4, 83.4, 82.3, 77.5, 69.9, 53.9, 53.8, 40.40, 40.37. **HRMS(ESI)** Calcd. for $\text{C}_{25}\text{H}_{24}\text{BrN}_2\text{O}_4$ ($\text{M} + \text{H}$) $^+$ 495.0914, found 495.0905.

Methyl 2-(4-bromophenyl)-2-(1-(4-(dimethylamino)phenyl)-3-oxoisoindolin-1-yl)-2-hydroxyacetate (3q). White solid, *syn/anti* isomer (10:13) ratio.



Mixture of (*syn* : *anti* = 10:13) isomers of **3q** (61% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.14 (d, $J = 7.8$ Hz, 1H), 8.05 (s, 1.3H), 8.03 (s, 1H), 7.75 (d, $J = 7.4$ Hz, 1H), 7.66 (t, $J = 7.4$ Hz, 1.3H), 7.59 – 7.52 (m, 2.6H), 7.52 – 7.47 (m, 2H), 7.41 (t, $J = 8.3$ Hz, 3.6H), 7.35 (d, $J = 7.6$ Hz, 2.3H), 7.21 – 7.12 (m, 7.2H), 6.53 (s, 2H), 4.31 (s, 1H), 4.10 (s, 1.3H), 3.86 – 3.81 (m, 15.6H), 3.80 (s, 3H), 3.69 (s, 6H), 3.57 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 172.7, 172.4, 171.7, 171.6, 170.0, 169.7, 153.0, 152.4, 146.5, 146.1, 138.1, 135.9, 135.7, 134.6, 132.6, 132.5, 132.0, 131.9, 131.5, 131.1, 130.7, 129.5, 129.3, 129.0, 128.6, 126.4, 126.1, 123.9, 123.43, 123.40, 123.3, 106.1, 104.7, 83.7, 82.2, 71.5, 70.2, 61.0, 56.4, 56.2, 53.98, 53.95. **HRMS(ESI)** Calcd. for $\text{C}_{26}\text{H}_{24}\text{BrNNaO}_7$ ($\text{M} + \text{Na}$) $^+$ 564.0628, found 564.0602.


Methyl 2-(benzyloxy)-2-(4-bromophenyl)-2-(1-(4-methoxy-3-methylphenyl)-3-oxoisindolin-1-yl)acetate (3r). White solid, *syn/anti* isomer (1:1) ratio.



anti-3r

anti-3r (43% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.10 (d, $J = 7.8$ Hz, 1H), 7.67 (d, $J = 7.5$ Hz, 1H), 7.54 (t, $J = 7.6$ Hz, 1H), 7.43 – 7.35 (m, 7H), 7.30 (d, $J = 8.5$ Hz, 2H), 7.20 (dd, $J = 18.0, 8.6$ Hz, 4H), 6.64 (d, $J = 8.7$ Hz, 1H), 4.69 (d, $J = 11.1$ Hz, 1H), 4.26 (d, $J = 11.2$ Hz, 1H), 3.79 (s, 3H), 3.41 (s, 3H), 2.13 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 169.8, 169.6, 157.5, 146.9, 137.8, 132.5, 131.8, 131.48, 131.45, 130.9, 130.5, 128.7, 128.6, 128.5, 127.8, 127.6, 127.1, 126.7, 125.5, 123.5, 123.3, 108.6, 89.7, 71.6, 69.0, 55.3, 52.1, 16.3. **HRMS(ESI)** Calcd. for $\text{C}_{32}\text{H}_{28}\text{BrNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 608.1043,


found 608.1026.



syn-3r


syn-3r (43% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.79 (d, $J = 7.6$ Hz, 1H), 7.68 (d, $J = 6.3$ Hz, 2H), 7.56 (d, $J = 7.2$ Hz, 1H), 7.45 – 7.36 (m, 7H), 7.25 – 7.16 (m, 3H), 6.72 (d, $J = 9.3$ Hz, 3H), 4.91 (d, $J = 10.9$ Hz, 1H), 4.19 (d, $J = 10.9$ Hz, 1H), 3.79 (s, 3H), 3.62 (s, 3H), 2.15 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 171.8, 169.4, 157.6, 147.2, 138.1, 132.4, 131.9, 131.8, 131.3, 131.1, 129.4, 129.3, 128.8, 128.7, 128.3, 128.1, 126.9, 126.4, 125.1, 123.6, 123.4, 109.5, 91.9, 71.0, 70.4, 55.4, 52.5, 16.6. **HRMS(ESI)** Calcd. for $\text{C}_{32}\text{H}_{28}\text{BrNNaO}_5$ ($\text{M} + \text{Na}$) $^+$ 608.1043, found 608.1037.

Methyl 2-(benzyloxy)-2-(4-bromophenyl)-2-(1-(4-(dimethylamino)phenyl)-3-oxoisindolin-1-yl)acetate (3s). White solid, *syn/anti* isomer (1:1) ratio.



anti-3s

anti-3s (41% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 8.04 (d, $J = 7.9$ Hz, 1H), 7.65 (d, $J = 7.5$ Hz, 1H), 7.50 (t, $J = 7.3$ Hz, 1H), 7.43 – 7.30 (m, 10H), 7.23 (d, $J = 8.4$ Hz, 2H), 6.72 (s, 1H), 6.55 (d, $J = 8.7$ Hz, 2H), 4.66 (d, $J = 11.2$ Hz, 1H), 4.24 (d, $J = 11.2$ Hz, 1H), 3.42 (s, 3H), 2.92 (s, 6H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 170.0, 169.5, 150.7, 150.1, 138.0, 132.9, 131.9, 131.4, 131.0, 130.7, 129.6, 128.7, 128.6, 127.9, 127.7, 126.8, 124.4, 123.5, 123.4, 111.3, 90.0, 71.6, 69.2, 52.3, 40.4. **HRMS(ESI)** Calcd. for $\text{C}_{32}\text{H}_{29}\text{BrN}_2\text{NaO}_4$ ($\text{M} + \text{Na}$) $^+$ 607.1203, found 607.1212.




syn-3s

syn-3s (41% yield): $^1\text{H NMR}$ (400 MHz, Chloroform-*d*) δ 7.82 (d, $J = 7.5$ Hz, 1H), 7.74 (d, $J = 8.8$ Hz, 2H), 7.55 (d, $J = 7.3$ Hz, 1H), 7.46 – 7.33 (m, 7H), 7.22 (d, $J = 9.6$ Hz, 3H), 6.75 (s, 2H), 6.62 (d, $J = 8.8$ Hz, 2H), 4.95 (d, $J = 11.0$ Hz, 1H), 4.18 (d, $J = 11.0$ Hz, 1H), 3.63 (s, 3H), 2.92 (s, 6H). $^{13}\text{C NMR}$ (100 MHz, Chloroform-*d*) δ 171.8, 169.4, 150.1, 147.5, 138.2, 132.7, 131.9, 131.7, 131.0, 129.5, 128.63, 128.60, 128.3, 128.0, 127.6, 126.94, 126.91, 123.5, 123.3, 112.0, 92.1, 71.0, 70.2, 52.5, 40.4. **HRMS(ESI)** Calcd. for $\text{C}_{32}\text{H}_{30}\text{BrN}_2\text{O}_4$ ($\text{M} + \text{H}$) $^+$ 585.1383, found 585.1362.



found 585.1362.

8. ^1H , ^{19}F and ^{13}C NMR spectra for products 3



^1H NMR (400 MHz, CD_3OD) and ^{13}C NMR (100 MHz, CD_3OD) spectra for 3a





^1H NMR (400 MHz, CD_3CN) and ^{13}C NMR (100 MHz, CD_3CN) spectra for **3b**





^1H NMR (400 MHz, CDCl_3) and ^{13}C NMR (100 MHz, CDCl_3) spectra for **3c**





^1H NMR (400 MHz, CD_3CN) and ^{13}C NMR (100 MHz, CD_3CN) spectra for *anti*-3d





^1H NMR (400 MHz, CD_3CN) and ^{13}C NMR (100 MHz, CD_3CN) spectra for *syn*-3d






^1H NMR (400 MHz, CDCl_3), ^{13}C NMR (100 MHz, CDCl_3) and ^{19}F NMR (376 MHz, CDCl_3) spectra for *anti*-3e








¹H NMR (400 MHz, CDCl₃), ¹³C NMR (100 MHz, CDCl₃) and ¹⁹F NMR (376 MHz, CDCl₃) spectra for 3e






^1H NMR (400 MHz, CD_3CN), ^{13}C NMR (100 MHz, CD_3CN) and ^{19}F NMR (376 MHz, CD_3CN) spectra for *anti*-3f






anti-3f




¹H NMR (400 MHz, CDCl₃), ¹³C NMR (100 MHz, CDCl₃) and ¹⁹F NMR (376 MHz, CDCl₃) spectra for *syn-3f*



8.25
8.11
8.09
7.79
7.76
7.59
7.57
7.55
7.53
7.52
7.39
7.38
7.35
7.33
7.28
7.26
6.87
6.84
6.81
6.79

4.22
3.83
3.78







syn-3f








^1H NMR (400 MHz, CD_3OD), ^{13}C NMR (100 MHz, CD_3OD) and ^{19}F NMR (376 MHz, CD_3OD) spectra for **3g**







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for 3h







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for anti-3i







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *anti-3j*







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *syn*-3j







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for 3k







¹H NMR (400 MHz, CD₃CN) and ¹³C NMR (100 MHz, CD₃CN) spectra for *anti*-3l







¹H NMR (400 MHz, CD₃CN) and ¹³C NMR (100 MHz, CD₃CN) spectra for *syn*-31







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *anti*-3n







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *syn*-3n







^1H NMR (400 MHz, CDCl_3) and ^{13}C NMR (100 MHz, CDCl_3) spectra for **anti-3o**







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *syn*-3o****







^1H NMR (400 MHz, CDCl_3) and ^{13}C NMR (100 MHz, CDCl_3) spectra for 3p







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for **3q**







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for anti-3r







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *syn*-3r****





¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *anti-3s*





¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra for *syn*-3s

